Peptide record

TPDB92109

Cecropin A Antibacterial Anticancer Antifungal Antiparasitic Antiviral Toxicity modified_plain modified
37 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.

Standard-residue backbone model; source-recorded chemical modifications are not verified in these coordinates.

TPDB92109
Cecropin A
Antibacterial Anticancer Antifungal Antiparasitic Antiviral Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
AntiBP3 dbAMP DRAMP Peptipedia ACP740 _ACP240 AntiCP 2.0 CancerPPD 2.0 SATPdb dbACP iACP-DRLF Antifungipept dbAMP 3.0 AI4AVP DRAVP 2.0
modified_plain
Yes
A 37-aa modified multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from AntiBP3, dbAMP, DRAMP, and other sources, with an available 3D structural model.
C-terminal: Amidation
Sequence
KWKLFKKIEKVGQNIRDGIIKAGPAVAVVGQATQIAK-NH2
Physicochemical Analysis

Sequence-only estimates are not provided for modified or non-standard source notation. Reported molecular properties, when available, are retained below with their source records.

Chemical Descriptors
37 reviewed residue count
Amidation Activity
L Activity
Linear Activity
Free Activity
Antimicrobial Activity
Hyalophora Cecropia(silkmoth) Activity
Evidence Records 12 records
Evidence 1 Activity

Activity

IC50
IC50=251.47 µg/ml
Anticancer
251.47 µg/mL

Target

Bladder Cancer
486P
Bladder

Assay & Model

WST-1 assay
48-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2008

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation. dbAMP 3.0 classified as Anticancer under the disease-associated peptide function classes.
Evidence 2 Activity

Activity

IC50
IC50=231.26 µg/ml
Anticancer
231.26 µg/mL

Target

Bladder Cancer
RT4
Bladder

Assay & Model

WST-1 assay
48-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2008
Evidence 3 Activity

Activity

IC50
IC50=185.39 µg/ml
Anticancer
185.39 µg/mL

Target

Bladder Cancer
647V
Bladder

Assay & Model

WST-1 assay
48-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2008
Evidence 4 Activity

Activity

IC50
IC50=212.07 µg/ml
Anticancer
212.07 µg/mL

Target

Bladder Cancer
J82
Bladder

Assay & Model

WST-1 assay
48-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2008
Evidence 5 Activity

Activity

IC50
IC50=69.2 µg/ml
Anticancer
69.2 µg/mL

Target

Bladder Cancer
486P
Bladder

Assay & Model

Cell Viability assay
48-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2008
Evidence 6 Activity

Activity

IC50
IC50=96.22 µg/ml
Anticancer
96.22 µg/mL

Target

Bladder Cancer
RT4
Bladder

Assay & Model

Cell Viability assay
48-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2008
Evidence 7 Activity

Activity

IC50
IC50=28.74 µg/ml
Anticancer
28.74 µg/mL

Target

Bladder Cancer
647V
Bladder

Assay & Model

Cell Viability assay
48-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2008
Evidence 8 Activity

Activity

IC50
IC50=99.01 µg/ml
Anticancer
99.01 µg/mL

Target

Bladder Cancer
J82
Bladder

Assay & Model

Cell Viability assay
48-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2008
Evidence 9 Activity

Activity

IC50
IC50=373.3/ µg/ml
Anticancer
373.3

Target

Bladder Cancer
486P
Bladder

Assay & Model

LDH leakage assay
48-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2008
Evidence 10 Activity

Activity

IC50
IC50=289.3 µg/ml
Anticancer
289.3 µg/mL

Target

Bladder Cancer
RT4
Bladder

Assay & Model

LDH leakage assay
48-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2008
Evidence 11 Activity

Activity

IC50
IC50=200.7 µg/ml
Anticancer
200.7 µg/mL

Target

Bladder Cancer
647V
Bladder

Assay & Model

LDH leakage assay
48-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2008
Evidence 12 Activity

Activity

IC50
IC50=319.2 µg/ml
Anticancer
319.2 µg/mL

Target

Bladder Cancer
J82
Bladder

Assay & Model

LDH leakage assay
48-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2008